KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) Return on Sales: 2013-2025

Historic Return on Sales for Travere Therapeutics (TVTX) over the last 12 years, with Sep 2025 value amounting to -0.06%.

  • Travere Therapeutics' Return on Sales fell 5.00% to -0.06% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.06%, marking a year-over-year decrease of 5.00%. This contributed to the annual value of -0.00% for FY2024, which is 183.00% down from last year.
  • Latest data reveals that Travere Therapeutics reported Return on Sales of -0.06% as of Q3 2025, which was up 59.95% from -0.16% recorded in Q2 2025.
  • In the past 5 years, Travere Therapeutics' Return on Sales registered a high of 2.21% during Q3 2023, and its lowest value of -1.29% during Q4 2021.
  • Its 3-year average for Return on Sales is 0.69%, with a median of 0.49% in 2023.
  • Per our database at Business Quant, Travere Therapeutics' Return on Sales skyrocketed by 281bps in 2023 and then plummeted by 222bps in 2024.
  • Over the past 5 years, Travere Therapeutics' Return on Sales (Quarterly) stood at -1.29% in 2021, then spiked by 177bps to 0.48% in 2022, then spiked by 134bps to 1.82% in 2023, then crashed by 183bps to -0.00% in 2024, then declined by 5bps to -0.06% in 2025.
  • Its Return on Sales was -0.06% in Q3 2025, compared to -0.16% in Q2 2025 and -0.15% in Q1 2025.